FIG.1

SEQ ID NO: 1 - Amino acid sequence of heavy chain of humanized anti-HER2 monoclonal antibody

EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSV
KGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSASTKGPSV
FPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
SSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI
SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK
EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEW
ESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSP
GK

FIG.2

SEQ ID NO: 2 - Amino acid sequence of light chain of humanized anti-HER2 monoclonal antibody

DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSG
SRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSG
TASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVY
ACEVTHQGLSSPVTKSFNRGEC

FIG.3



1200
1000
800
600
400
200
0
Tumor volume (mm3)
10
20
30
40
Days after tumor inoculation
control
Trastuzumab
Antibody-drug conjugate
(27)

FIG.4



1600
1400
1200
1000
800
600
400
200
0
Tumor volume (mm3)
0
10
20
30
40
Days after tumor inoculation
control
Trastuzumab emtansine
Antibody-drug conjugate (8)
Antibody-drug conjugate (28)

FIG.5



700
600
500
400
300
200
100
0
Tumor volume (mm3)
10
20
30
40
Days after tumor inoculation
control
Trastuzumab
Trastuzumab emtansine
Antibody-drug conjugate (8)
Antibody-drug conjugate (29)
Antibody-drug conjugate (30)

FIG.6



1600
1400
1200
1000
800
600
400
200
0
Tumor volume(mm3)
15
25
35
45
55
Days after tumor inoculation
control
Trastuzumab
Trastuzumab emtansine
Antibody-drug conjugate (31)

FIG.7



1000
800
600
400
200
0
Tumor volume (mm3)
5
15
25
35
Days after tumor inoculation
control
Antibody-drug conjugate(50)
0.3 mg/kg
Antibody-drug conjugate(50)
1 mg/kg
Antibody-drug conjugate(50)
3 mg/kg
Antibody-drug conjugate(50)
10 mg/kg

FIG.8



2500
2000
1500
1000
500
0
Tumor volume (mm3)
0
5
10
15
20
Days after drug treatment
control
Trastuzumab
Trastuzumab emtansine
Antibody-drug conjugate
(50)

FIG.9



2000
1500
1000
500
0
Tumor volume (mm3)
0
5
10
15
20
25
Days after drug treatment
control
Trastuzumab
Trastuzumab emtansine
Antibody-drug conjugate(50)

FIG.10



1200
1000
800
600
400
200
0
Tumor volume (mm3)
0
10
20
30
Days after drug treatment
control
Trastuzumab
Trastuzumab emtansine
Antibody-drug conjugate
(50)

FIG.11



3000
2500
2000
1500
1000
500
0
Tumor volume (mm3)
0
5
10
15
20
25
Days after drug treatment
control
Trastuzumab
Trastuzumab emtansine
Antibody-drug conjugate
(50)

FIG. 12



900
800
700
600
500
400
300
200
100
0
Tumor volume (mm3)
0
10
20
30
Days after drug treatment
control
Trastuzumab
Trastuzumab emtansine
Antibody-drug conjugate (50)

FIG. 13




3500
3000
2500
2000
1500
1000
500
0
Tumor volume (mm3)
0
10
20
30
Days after drug treatment
control
Trastuzumab
Trastuzumab emtansine
Antibody-drug conjugate
(50)

FIG.14


3000
2500
2000
1500
1000
500
0
Tumor volume (mm3)
0
10
20
Days after drug treatment
control
Trastuzumab
Trastuzumab emtansine
Antibody-drug conjugate
(50)